Poster Session 1: Lymphoma/Multiple Myeloma
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Early during the Course of Disease Appears to Improve Outcomes of Patients T Cell Non-Hodgkin Lymphoma: Results of a Single-Institution Experience
Ernesto Ayala, H. Lee Moffitt Cancer Center;
Marcie Riches, MD, MS, H. Lee Moffitt Cancer Center;
Mohamed Kharfan-Dabaja, M.D., H. Lee Moffitt Cancer Center;
Frederick Locke, H. Lee Moffitt Cancer Center;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Teresa Field, MD PhD, H. Lee Moffitt Cancer Center;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center;
Joseph Pidala, MD, MS, H. Lee Moffitt Cancer Center and Research Institute;
Brian Betts, MD, H. Lee Moffitt Cancer Institute;
Asmita Mishra, MD, H. Lee Moffitt Cancer Center;
Jose-Leonel Ochoa, MD, H. Lee Moffitt Cancer Center;
Lia Elena Perez, M.D., H. Lee Moffitt Cancer Center;
Melissa Alsina, MD, H. Lee Moffitt Cancer Center and Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Trial of Carfilzomib + Melphalan (CarMel) Conditioning and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Relapsed Multiple Myeloma (MM)
Luciano J. Costa, MD, PhD, Medical University of South Carolina;
Heather Landau, MD, Memorial Sloan-Kettering Cancer Center;
Jagadish K Venkata, PhD, Medical University of South Carolina;
Yubin Kang, MD, Medical University of South Carolina;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
David J. Chung, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Nikoletta Lendvai, MD, Memorial Sloan-Kettering Cancer Center;
Tricia Bentz, MUSC;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center
A Multidisciplinary Team Approach for Diagnosis and Treatment of Patients with AL Amyloidosis
Kathleen T Finn, NP, Boston Medical Center;
Salli Fennessey, Boston Medical Center;
Anthony C Shelton, RN, Boston Medical Center;
Dina Brauneis, NP, Boston Medical Center;
Taylor Teschner, Boston Medical Center;
Karen Quillen, MD, Boston Medical Center;
J. Mark Sloan, MD, Boston Medical Center;
Anne S. Renteria, MD, Boston Medical Center;
David C Seldin, MD, PhD, Boston Medical Center;
Vaishali Sanchorawala, MD, Boston Medical Center
CD96 Antibody Based Elimination of AML Leukemic Stem Cells As a New Strategy in Stem Cell Transplantation
Martin Gramatzki, MD, Division of Stem Cell Transplantation and Immunotherapy;
Christian Kellner, Ph.D., Division of Stem Cell Transplantation and Immunotherapy;
Matthias Peipp, Ph.D., Division of Stem Cell Transplantation and Immunotherapy;
Natalie Schub, M.D., Division of Stem Cell Transplantation and Immunotherapy;
Andreas Humpe, M.D., Division of Stem Cell Transplantation and Immunotherapy;
Matthias Staudinger, Ph.D., Division of Stem Cell Transplantation and Immunotherapy
A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results
Ann LaCasce, Dana-Farber Cancer Institute;
Ahmed Sawas, Columbia University Medical Center;
R. Gregory Bociek, University of Nebraska Medical Center;
Stephen Ansell, Mayo Clinic;
Julie M. Vose, MD, University of Nebraska Medical Center;
Megan O'Meara, Seattle Genetics, Inc.;
Ranjana Advani, Stanford Cancer Center
Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning for Consolidation of VGPR or CR in Myeloma
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jose Leonel Ochoa-Bayona, MD, H. Lee Moffitt Cancer Center and Research Institute;
Daniel Sullivan, MD, MS, H. Lee Moffitt Cancer Center and Research Institute;
Rachid Baz, MD, H. Lee Moffitt Cancer Center and Research Institute;
Kenneth Shain, MD, H. Lee Moffitt Cancer Center and Research Institute;
Ryan Hillgruber, H. Lee Moffitt Cancer Center and Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute;
Melissa Alsina, MD, H. Lee Moffitt Cancer Center and Research Institute
Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
Jennifer Le Rademacher, PhD, Medical College of Wisconsin;
Christopher Flowers, MD, Emory University;
Michael Lill, MD, Cedars Sinai Medical Center;
Luciano J. Costa, MD, PhD, Medical University of South Carolina;
Tsiporah B. Shore, MD, FRCPC, FACP, Cornell Medical Center Hematology/Oncology, The New York Hospital;
William Vaughan, MD, University of Alabama in Birmingham;
Michael Craig, MD, West Virginia University - Health Science Center;
Cesar O. Freytes, MD, South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio;
Thomas C. Shea, MD, University of North Carolina at Chapel Hill;
Mitchell E. Horwitz, MD, Duke University Medical Center;
Joseph W. Fay, MD, FACP, Baylor University Medical Center;
Shin Mineishi, MD, University of Alabama at Birmingham;
Damiano Rondelli, MD, University of Illinois Hospital & Health Sciences System;
James Mason, MD, Scripps Clinic;
Vijay Reddy, MD, PhD, University of Florida;
Ira Braunschweig, MD, Montefiore Medical Center;
Weiyun Ai, MD, PhD, University of California San Francisco;
Elizabeth Armstrong, MS, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Angela Smith, MS, PA, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Cathy Zhao, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Agnes Elekes, MD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Jeanette Carreras, MPH, Medical College of Wisconsin;
Kazunobu Kato, MD, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.;
Edmund K. Waller, MD, PhD, Emory University
Synergistic Cytotoxicity of Gemcitabine, Clofarabine and Edelfosine (± DNA alkylating agent) in Lymphoma Cell Lines
Ben C. Valdez, PhD, UT MD Anderson Cancer Center;
Axel Zander, MD, PhD, FACP, Universitatsklinikum Hamburg-Eppendorf;
Guiyun Song, PhD, UT MD Anderson Cancer Center;
David Murray, PhD, Cross Cancer Institute;
Yago L. Nieto, MD, PhD, University of Texas MD Anderson Cancer Center;
Yang Li, MS, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, UT MD Anderson Cancer Center
Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience
Kitsada Wudhikarn, MD, Stanford University Medical Center;
Philip Lavori, PhD, Stanford University School of Medicine;
Sally Arai, MD, Stanford University Medical Center;
Laura Johnston, MD, Stanford University Medical Center;
Ginna G. Laport, MD, Stanford University Medical Center;
Robert Lowsky, MD, Stanford University Medical Center;
David B. Miklos, MD, PhD, Stanford University Medical Center;
Judith A. Shizuru, MD, PhD, Stanford University Medical Center;
Richard T Hoppe, MD, Stanford University Medical Center;
Jonathan Benjamin, MD, PhD, Stanford University Medical Center;
Everett Meyer, MD, PhD, Stanford University Medical Center;
Robert Negrin, MD, Stanford University Medical Center;
Wen-Kai Weng, MD, Stanford University Medical Center
